Quvara Medical Launches as Latest CDMO, Joining a Growing Trend in Pharmaceutical Manufacturing

The pharmaceutical contract development and manufacturing organization (CDMO) landscape continues to evolve with the launch of Quvara Medical, the latest addition to a growing list of new CDMOs in 2025. This development highlights the ongoing transformation in the pharmaceutical manufacturing sector, with several new players entering the market to meet increasing demand for specialized production services.

Quvara Medical Emerges from Becton Dickinson Acquisition

Quvara Medical, a creation of the Buckland Group, has made its debut following the acquisition of a former Becton Dickinson manufacturing facility in Swindon, England. The company aims to focus on high-precision, high-volume production for both the medical device and pharmaceutical industries. While the financial terms of the deal remain undisclosed, Quvara Medical has confirmed that the facility will continue operations with full workforce retention.

Paul Bragg, Managing Director of Buckland Group, emphasized the strategic nature of this acquisition, stating, "This acquisition is part of our strategy to build specialised, sector-leading businesses under the Quvara Group banner. Medical manufacturing is the first—but not the last area where we're applying this model."

The Swindon facility, which has been operational for two decades, brings with it a specialization in manufacturing prefilled syringes. This expertise aligns well with the increasing demand for injectable drug delivery systems in the pharmaceutical industry.

A Year of CDMO Launches and Acquisitions

Quvara Medical's entry into the market is part of a larger trend in the CDMO space, with at least five new CDMOs launching in 2025 alone. These include:

1. Rezon Bio: Launched in September with two manufacturing sites in Poland, focusing on biologics.
2. Codis: Formed through the combination of U.S.-based Particle Dynamics and a UK spray drying plant previously operated by EuroAPI.
3. Meribel: Debuted in April after acquiring production sites from Recipharm and purchasing France's Synerlab.
4. Artis BioSolutions: A cell and gene therapy CDMO that also launched in April.

This flurry of activity in the CDMO sector reflects the pharmaceutical industry's increasing reliance on specialized manufacturing partners. The trend towards outsourcing complex manufacturing processes has been driven by factors such as the rise of biologics, gene therapies, and other advanced medicinal products that require specialized production capabilities.

Neil Sibley, Chief Executive of Quvara Medical, highlighted the company's value proposition: "We offer clients the speed, agility, and compliance they demand, built on decades of manufacturing excellence." This statement underscores the importance of flexibility and regulatory compliance in the competitive CDMO landscape.

As the pharmaceutical industry continues to evolve, with an increasing focus on personalized medicine and complex biologics, the role of CDMOs is likely to become even more critical. The launch of Quvara Medical and its counterparts represents a response to this shifting landscape, promising to provide pharmaceutical companies with the specialized manufacturing capabilities they need to bring innovative treatments to market.